Clinical Trials Logo

Clinical Trial Summary

The pharmacogenomics of the Colombian population with rheumatoid arthritis (RA), understood as the individual response to drugs depending on the genome of each patient, can be an explanation for the problems of effectiveness and safety that appear during the pharmacotherapeutic treatment of RA.

Currently, there are limited studies on the pharmacogenomics of the Colombian population; Therefore, it is necessary to identify and classify the genetic polymorphisms characteristic of Colombian patients with RA, which influence the response of methotrexate, infliximab, etanercept, adalimumab and thus contribute to precision medicine and medical prescription according to the Specificity of the genome of each patient.

This project aims to determine the association of genetic polymorphisms with the response to inhibitors of tumor necrosis factor alpha (TNFα) and methotrexate. To do this, a prospective study of cases and controls will be performed in patients in 3 hospital of Colombia with pharmacotherapeutic treatment of methotrexate, infliximab, etanercept, adalimumab, in monotherapy or combination therapy.

As a result, it is expected to contribute to the performance of specific genetic tests for RA and the generation of a pharmacogenomic basis of the Colombian population with RA.


Clinical Trial Description

Rheumatoid arthritis is an important public health problem; In recent years better health outcomes have been achieved with the incorporation of synthetic and biological disease modifying drugs. However, problems of variability in response are reported, leading to ineffectiveness and adverse reactions in 30-40% of patients. In this sense, Pharmacogenomics, through the study of genetic variants of proteins involved in the pharmacokinetics and pharmacodynamics of drugs, becomes a way to maximize the efficacy and safety of pharmacotherapy.

This work aims to give an overview of the pharmacogenomics of rheumatoid arthritis and the possibility of using genetic tools to support the pharmacotherapeutic decision in the clinical consultation, in order to improve the response to treatment of this disease.

The relevance of this study is to provide the possibility of applying the candidate genes selected for their biological importance, either in the kinetics or by their relation in the pharmacological action, in the identification of individuals at risk of adverse effects or With probability of being resistant to the treatment. Therefore, it is expected that the information generated will be able to be used in daily clinical practice, contributing to identify the best therapeutic option (greater effectiveness and safety) in patients with rheumatoid arthritis. In addition, it is expected that this type of information will contribute to optimize the costs of care in this disease, which is classified in Colombia as a high cost pathology, in which medicines can reach up to 86% of the total cost.

Overall, individuals respond differently to drug therapy and no medication is 100% effective in all patients, which may be due to an alteration in the pharmacokinetics and pharmacodynamics of drugs associated with conditions Genetic-environmental. In this context, the study of candidate pharmacogenomic genes has been most successful in identifying and explaining variation in pharmacological response, compared to candidate gene investigations of the disease. Therefore, this work should contribute to the choice of the best therapeutic option in patients with RA in Colombia and, thus, to strengthen the country's health sector. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03352622
Study type Interventional
Source Universidad de Antioquia
Contact Yolima Puentes, Pharmacist
Phone +574-3135742922
Email yolimap16@gmail.com
Status Recruiting
Phase N/A
Start date October 17, 2017
Completion date September 17, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06040853 - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia? Phase 4
Not yet recruiting NCT05553496 - Assessment of Rituximab Therapeutic Response Versus Conventional Treatment Phase 2/Phase 3
Recruiting NCT05534802 - Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass N/A
Recruiting NCT04190537 - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed NCT03522532 - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid N/A
Completed NCT03119454 - "Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice N/A
Unknown status NCT01614353 - Medication-taking Preferences & Practices of Patients With Chronic Conditions N/A
Completed NCT03714360 - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery. Phase 4
Recruiting NCT06288841 - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study N/A
Not yet recruiting NCT04320277 - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Phase 2/Phase 3
Completed NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Phase 2
Completed NCT05591105 - Morphine Consumption in the Obese Patients
Not yet recruiting NCT03904303 - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep Phase 1
Not yet recruiting NCT05453045 - Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva N/A
Completed NCT05428683 - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery N/A
Enrolling by invitation NCT02985281 - Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Phase 2/Phase 3
Recruiting NCT06222710 - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy N/A
Not yet recruiting NCT03953287 - Pharmacokinetic Study of Paracetamol. Phase 1
Recruiting NCT03622047 - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil N/A
Active, not recruiting NCT06324370 - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) N/A